Who funds antibody research?

We count 205 funded antibody projects, active between 2020 and 2035, from 7 funders. The most came from EU · ERC (45 projects), NIH · NIAID (44 projects) and Wellcome (29 projects). The median award is $2.7M, across the 197 of 205 projects that list an amount.

Funded projects

205

Funders

7

Median award

$2.7M

Open calls now

2

Top funders of antibody research

Projects whose title or summary mentions antibody. Median award: of the projects that list an amount, in US dollars; “—” when fewer than 3 do.

Open antibody funding calls

2 open calls mention antibody today.

• Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
  European Commission · Horizon Europe€9,000,000 – €10,000,000Deadline: February 17, 2027 ·
• Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses
  European Commission · Horizon Europe€9,000,000 – €10,000,000Deadline: February 17, 2027 ·

Funded antibody projects

A sample, latest start first, at most three per program.

• Targeted Pathogen Degradation and its Synergy with Antiviral Immunity
  Wellcome · £3,000,000 · ends 2035
• How do African trypanosomes evade the complement system?
  Wellcome · £2,638,121 · ends 2034
• How Germinal Centres Shape Serum Antibody Responses
  Wellcome · £3,471,731 · ends 2033
• Amyloid clearing therapy in dementia with Lewy bodies plus Alzheimers disease (ACT DLB+)
  NIH · NINDS · $4,161,896 · ends 2033
• CAREER: Creating and evolving antibodies from scratch in yeast
  NSF · ENG · $647,941 · ends 2031
• Investigating Long-Term Antibody, B Cell, and T Cell Immunity in Ebola Survivors Using a Longitudinal Biobank
  UKRI · MRC · £1,501,831 · ends 2031
• The Pirbright Institute — Agricultural Development
  Gates Foundation · $3,865,802 · ends 2030
• The Ante-Amyloid Treatment of Alzheimer's disease (A3) Trial and Alzheimer Plasma EXtension (APEX) Study
  NIH · NIA · $6,467,513 · ends 2030
• Immune imprinting and immune responses to influenza viruses with pandemic potential
  NIH · NIAID · $3,160,180 · ends 2030
• Regulated, Long-Term Expression of Anti-HIV Antibodies via B Cell Receptor-Targeted Lentiviral Transduction
  NIH · NIAID · $5,927,367 · ends 2030

How we count

Funded projects come from public award records (NIH RePORTER, NSF, EU CORDIS, UKRI Gateway to Research, Wellcome, the Gates Foundation, DOE, NASA and USDA NIFA) whose title or summary matches “antibody or antibodies”. NIH lists each budget year separately; one project counts once. Amounts are as the funder lists them; medians use only projects that list one, in US dollars. Open calls and forecasts are from our listings of October 28, 2026. A project can mention a topic without being mainly about it, so treat the counts as a guide to who funds the area.